Skip to main content

EuroAPI launches strategic review

1st March 2024

Submitted by:

Andrew Warmington

During its full-year results presentation, CDMO and API supplier EuroAPI announced the launch of Focus-2027, a comprehensive project that will seek to unlock profitable growth and increase returns. Key means of achieving include:

* Streamlining the value-added API portfolio by discontinuing 13 with low or negative margins and focusing on highly differentiated, profitable products, such as vitamin B12, prostaglandins, peptides and oligonucleotides

* Having a focused CDMO offer “leveraging our recognised capabilities and technology platforms” *

Rationalising its industrial footprint to prioritise high-return capex and create “a leaner organisation with more efficient ways of working”

This is all subject to various local information and consultation processes with employee representatives, and agreements with stakeholders. EuroAPI plans to reveal the outcome during Q2.

The company added that its key objective for 2024 under new CEO Ludwig de Mot is to “focus on cash in a year of transition”. It has signed amended contractual terms with Sanofi, from which it was originally spun out, and is having discussions with key stakeholders on finance. Both Sanofi and EPIC BpiFrance have agreed to extend the lock-up of their stakes until December 2025.

In 2023, sales increased by 3.8% to €1,013.2 million. However, core EBITDA was down by 22.4% to €93.7 million and the core EBITDA margin, fell from 12.3% in 2022 to 9.2% due to unfavourable fixed cost absorption and input cost inflation. The company had to take a €226.4 million impairment on tangible assets and had a net loss of €189.7 million, over 12 times more than in 2022.

In 2024, EuroAPI anticipates a 4-7% decrease in net sales on a comparable basis, largely driven by a continuing fall in sales to Sanofi. The core EBITDA margin is expected to fall further to 6-9%. The company added that there will be a material impact from transformation and early restructuring costs, including industrial under-activity resulting from Focus-27.

CDMO sales were the bright spot in 2023, growing by 6.8% to €285.8 million. Sales to Sanofi were 6.3% up as commercial projects progressed despite the discontinuation of two late-stage programs at the end of 2022. Meanwhile, sales to other clients grew 7.2%, driven mainly by increased sales from commercial products. In all, 69 projects were active at the end of 2023 and 23 new contracts were signed, of which 12 were in the pre-approval or commercial phase, spurred by increasing demand for peptides and oligonucleotides, complex chemistry re-shoring and dual sourcing with European players.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington